Winter Huang -- Chairman, CEO
Mr. Huang is a successful entrepreneur with extensive entrepreneurial experience in a broad range of different types of business. Mr. Huang was originally engaged in the business of petroleum, chemical, commercial distribution and other industries. Since the early 90s, he had been mainly engaged in the research and development of botanical drugs and since then has been committed to the research of life sciences. Mr. Huang is the founder of Pegasus Pharmaceutical Group. Mr. Huang has been the key person in the development of the CARESENG® series. Under his great leadership through the past 20 years, Mr. Huang established Pegasus Pharmaceuticals on a solid foundation in terms of novel drug development, clinical applications, and preventive medicine development.
James Cao, MBA, CFA --- General Manager and Chief Financial Officer
Mr. Cao graduated from Shanghai Jiaotong University with a Bachelor of Applied Mathematics, and a Master degree of Systems Engineering. With more than 15 years of experience in finance, investment and financial management, Mr. Cao was the Executive Manager of the Investment Division of a large holding company in Shanghai China where he managed the whole investment portfolio. Prior to joining Pegasus Pharmaceuticals, he received the MBA degree from the Saunder School of Business in the University of British Columbia (UBC) of Canada and was a consultant to the School.
HongDa Wang, Senior Business Manager --- Special Assistant to the Chairman, Chief Representative of the Biopark Project in China
In 1983, Mr. Wang graduated from the Academy of Social Sciences Graduate School of China with a master's degree of Journalism. Specializing in policy research and administration, Mr. Wang had many years of working experience in the government of China. He is currently the Special Assistant to the Chairman of Pegasus Pharmaceuticals Group and the Chief Representative of the Biopark project in China.
JieWen Liu, Senior Business Manager --- Special Assistant to the Chairman, Chief Representative of the Biopark Project in China
Mr. Liu had been engaged in business in China for many years. As an economist, Mr. Liu had been working in the commercial division of the government of China. He had always been a President and General Manager of a private company. Mr. Liu is currently employed as a Special Assistant to the Chairman of Pegasus Pharmaceuticals Group and the Deputy Chief Representative of the Biopark project in China.
William Jia, Ph.D --- Chief Scientist
Dr.William Jia is the Tenured Professor of the School of medicine, University of British Columbia (UBC), Canada and a Senior Scientist of British Columbia Cancer Agency; served on the Scientific Review Panel at the National Cancer Institute of Canada and was appointed to Peer Review Panel for Canadian Institute of Health Research (CIHR). He has been honored with Chair Professorship in the School of Life Sciences at Fudan University.
He graduated from the Faculty of Biology, Fudan University, China in 1982, and obtained his PhD in molecular neurosciences from University of British Columbia (UBC) in 1992 under the supervision of Professor Dr. Max Cynader, a well-known developmental neurobiologist and director of the Brain Research Centre at UBC. He has over 20 years of research experience in many fields including molecular biology, cancer, gene therapy and neurology sciences. Dr. Jia was the first few scientists in the world using human Herpes simplex virus to treat cancer, which pioneered the field of oncolytic virotherapy for cancer treatment. His major contribution was the first to prove that genetic engineered virus could selectively destroy malignant brain cancer in an animal model with a competent immune system. This work was published in the highest ranked cancer journal: The Journal of National Cancer Institute with an editorial comments and gained a lot of attention in general public as well. The results were cited repeatedly at hearings of the US Congress for gene therapy and used as a critical evidence for the safety of gene therapy.
In recent years, Dr. Jia's interest has been in the study of natural products for anti-cancer and anti-viral infection effects. He has recently discovered that several plant-derived compounds not only possess strong tumor inhibitory effect but also can dramatically enhance the efficacy of conventional anti-tumor drugs. He was the first ever and discovered ginsenoside Rh2 not only competitively reverse the drug resistance on multidrug resistant tumor cells but also may further sensitize MDR tumor cells to chemotherapeutics for potential synergistic effects. He was inventor of "Ginsenoside Rh2 and its derivatives chemotherapy" and a patent application based on this finding has been obtained. The findings have translated into new drug research and development stage of a line of anticancer natural products. Most recently, Dr. Jia has proposed a new concept for drug development from traditional medicine. The concept is named "Post-Absorption/Metabolism Drug" or PAMD. This concept emphasizes on identifying and isolation of chemical components that are absorbed and presence in the blood and target organs after orally taken the medicine instead of original chemicals contained in herbs. Utilizing this concept, some novel lead compounds have been identified with potent pharmacological activity and extremely low toxicity, which are being developed for novel drug candidates.
In 2003, Dr. Jia and Dr. William Campbell, another scientist of Pegasus Pharmaceuticals, were the first in the world to map all the specific epitopes of SARS corona virus, which could be developed into diagnostic kits for SARS, and SARS vaccines. This research project has received government funding from the Canadian Institute of Health Research (CIHR).
In the past 10 years, Dr. Jia has received many awards and research funds from Canadian government agencies. Since 1997, he has been a Scholar of Canadian Institute of Health Research for his contribution in the field of gene therapy. Dr. Jia was listed as one of 20 outstanding medical scientists in Canada in the August 1999 TIME'S Canadian edition. He is the author of over 50 articles published in scientific journals, has presented over 50 papers at national and international scientific meetings, and is the holder of several patents.
William Campbell, Ph.D --- Senior Scientist of Proteomics
Dr. Campbell is the Director of Technology for Peptide Drugs at Pegasus Pharmaceuticals Group Inc. He obtained his PhD in Microbiology and immunology from the University of Montreal, Canada in 1971. Previously, Dr. Campbell held position at Choju Medical Institute, Japan as a senior scientist and attained the rank of Associate Professor at Nagoya City University, and has severed as an Associate Editor of Microbiology and Immunology. After leaving Japan, Dr. Campbell spent two years as Visiting Professor at the Kinsmen Laboratory of Neurological Research at the University of British Columbia before joining Pegasus Pharmaceuticals Group Inc. Dr. Campbell has over 30 year of experience in the field of protein chemistry. In 1989, while in Japan as an Associate Professor at Nagoya City University, he discovered a novel enzyme, carboxypeptidase R, an important regulator of inflammation and fibrinolysis. Over the past several years he has made use of novel computer algorithms that create peptide antibody mimetics to targets in proteins and has used peptide array technology to identify potential drug candidates for both therapeutic and diagnostic applications in infectious diseases, cancer, immune dysfunction syndrome and neurologic disorders. He and Dr. Jia were the first few scientists in the world using peptide array technology to probe and identify SARS CoV-specific epitopes. Dr. Campbell has authored more than 30 research papers and is contributing several most cited review articles.
Joshua Yu, Ph.D, Synthetic Chemistry Scientist
Dr. Joshua Yu received his doctoral degree from the University of Göttingen, Germany. He continued his post-doctoral research in the University of British Columbia (UBC), Canada. Dr. Yu has over 20 years of research experience in extraction and purification of active phytomedicinal compounds from herbs, modification of structure of the active molecules from herbs, and synthesis of small molecule compounds, Bioinorganic Chemistry, Organometallics and Nano-Cluster material Chemistry. Dr. Yu has published over 20 academic papers on various world renowned journals and magazines and had applied several technology patents.
Guosong Qiu, M.D., Ph.D, Project Manager
Dr. Guosong Qiu graduated from the School of Medicine, Zhejiang University with a Bachelor of Medicine, and a Master of Science degree in Cardiovascular. In Canada, Dr. Qiu received his doctoral degree in Pathology and Laboratory Medicine at the University of British Columbia. Specializing in the clinical non-invasive and interventional diagnosis and research of cardiovascular medicine, Dr. Qiu holds a membership of the Canadian Society of Atherosclerosis, Thrombosis, and Vascular Biology (CSATVB). Dr. Qiu has profound knowledge in the mechanism of atherogenesis and development of coronary heart disease, and also utilizes lentivirus to mediate RNA interference to investigate the gene functions. He also conducted in-depth research on the non-lipid lowering effects of statins.
Sherman Zhao, MD, Ph.D, Clinical Project Manager
Dr. Sherman Zhao graduated from the Shanghai Medical University with a bachelor's degree in laboratory medicine. At the Peking University, he received his doctoral degree in Pharmacology. When Dr. Zhao was later studying in the Georgia State University, United States, he completed his post-doctoral research. Prior to joining Pegasus, Dr. Zhao has gained profound knowledge and clinical experience in treating cancer and Alzheimer's disease and has published over 10 papers. He has also been engaged in the research and development of novel drugs in domestic and foreign pharmaceutical companies. Dr. Zhao was the key person involved in the development of two phytopharmaceuticals which were approved for clinical trial in 2005, and is the principal investigator of the undergoing Phase III clinical trial.
Martin Wang, Ph.D, Regulatory Affair Project Manager
Dr. Wang has been actively involved in the research and development of phytopharmaceuticals and nutraceutical products in the past 20 years. Prior to joining Pegasus Pharmaceutical Group Inc., he was a Research Associate in the Cross Cancer Institute, University of Alberta, Canada and had been mainly focusing on the research of the efficacy of nano drugs on lung cancer. Later as a Senior Analyst in the Division of Food and Natural Health Product (NHP), ALS Laboratory Group, Edmonton, Canada, Dr. Wang had been analyzing the active ingredients and nutrition in food and NHP. Before coming to Canada, Dr. Wang was an Associate Professor in the School of Pharmacy, Nanjing University of Traditional Chinese Medicine, China. Concurrently he also served as the Deputy Director of the Jiangsu Provincial Centre for Quality Control of Chinese Medicine. Dr. Wang has extensive experience in novel drug research from screening natural products as drug candidates to translational studies of investigational drugs as well as formulation, pilot-scale development, chromatographic fingerprinting profiles of finished botanical products, and quality control. He also has years of regulatory affairs experience with strong knowledge in the licensing of Canada NHP and US FDA botanical drug IND or food supplement as well as China SFDA novel drug applications. In 1997, Dr. Wang received his doctoral degree from the Nanjing University of Traditional Chinese Medicine, China. He finished his post-doctoral research in the Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan and then in Jinling Pharmaceutical Company, Nanjing, China. Dr. Wang has over 50 publications in peer-reviewed journals and 3 patents of novel botanical drugs in China. He joined Pegasus Pharmaceuticals Group Inc. in 2007 and is currently in charge of regulatory affairs.
Richard Zhang, M.D., Ph.D. Managing Director
Dr. Zhang graduated from Medical School of Shanghai Jiao Tong University (formerly Shanghai Second Medical College) and worked as a physician in the internal medicine department specialised in gastrointestinal. Then, he studied and worked in University of Turku in Finland and finished his doctor degree in medicine from Medical Biochemistry and Molecular Biology Department in 1995. His main research field was on wound healing process and the several research papers were published in the world-class journals. He also received the International Trade Certificate from Turku Polytechnic at that time. In 1996, he joined Finnish second largest pharmaceutical company as a product manager in international market department. Later, he served as a marketing manager in a multinational pharmaceutical company in China organization, and as a chief representative for a listed Finnish biotechnology company in China. With many years in life sciences field, He has extensive experiences in clinical, research, marketing, and business management.
Clint Cheng, MBA, Business Development Manager
Mr. Cheng was educated in both China and North America, having received an MBA degree from the Sauder Business School of University of British Columbia, Canada, and a Bachelor of Engineering degree from Tsinghua University, Beijing, China. He has extensive experiences in financing and investing in connection with business ventures of high growth potential. He participated in raising corporate funds and had substantial exposure to mergers/acquisitions, particularly in the areas involving public listing. Particularly, through his tenure with a biopharmaceutical company publicly traded in the United States and Canada, he acquired in-depth knowledge of the industry and drug development process, and supervised intellectual property matters including over 30 families of patent applications and trademarks.
